← ANALYST RATINGS · TIPRANKS
Taysha Gene Therapies (TSHA): analyst forecast and price target
Analyst consensus
Strong Buy8 Buy0 Hold0 Sell
Ratings of 8 analysts in the last 3 months12-month forecast
Based on 8 price targets given in the last 3 months, the average target is $14.00, the highest $19.00, the lowest $11.00. The average is +286.7% from the last price of $3.62.
Analyst ratings 15
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $3.50 → $4.00+14.3% | Hold | +10.5% | Reiterated | 17.10.26on TipRanks Oct 16 22:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $3.50 → $4.00+14.3% | Hold | +10.5% | Reiterated | 17.10.26on TipRanks Oct 16 22:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $3.50 → $4.00+14.3% | Hold | +10.5% | Reiterated | 17.10.26on TipRanks Oct 16 22:05 | — | |
| Biren Amin★★★★★★★★★★#1671 · hits 46% · avg +7.6% | Piper Sandler | $12.00 | Buy | +231.5% | Reiterated | 16.10.26on TipRanks 08:08 | −1.8% | ↗ |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $4.50 → $3.50−22.2% | Hold | −3.3% | Reiterated | 14.10.26on TipRanks 10:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $4.50 → $3.50−22.2% | Hold | −3.3% | Reiterated | 14.10.26on TipRanks 10:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $4.50 → $3.50−22.2% | Hold | −3.3% | Reiterated | 14.10.26on TipRanks 10:05 | — | |
| Kalpit Patel★★★★★★★★★★#1436 · hits 39% · avg +16.1% | Wolfe Research | — | Buy | — | Initiated | 17.09.26on TipRanks 07:25 | +0.6%next day −2.8% · 5 days −8.0% | ↗ |
| Tazeen Ahmad★★★★★★★★★★#1537 · hits 60% · avg +5.8% | Bank of America Securities | — | Buy | — | Reiterated | 14.08.26on TipRanks 11:15 | −0.5%next day +4.8% · 5 days +3.7% | ↗ |
| Unknown Analyst | Wells Fargo | $11.00 | Buy | +203.9% | Assigned | 12.08.26on TipRanks 06:55 | −4.4%next day −7.2% · 5 days +0.8% | ↗ |
| Gil Blum★★★★★★★★★★#949 · hits 43% · avg +12.5% | Needham | $12.00 | Buy | +231.5% | Reiterated | 12.08.26on TipRanks 06:45 | −4.4%next day −7.2% · 5 days +0.8% | ↗ |
| Kristen Kluska★★★★★★★★★★#457 · hits 48% · avg +23.3% | Cantor Fitzgerald | $19.00 | Buy | +424.9% | Reiterated | 11.08.26on TipRanks Aug 12 10:35 | +5.2%next day −4.4% · 5 days −6.9% | ↗ |
| Salveen Richter★★★★★★★★★★#967 · hits 51% · avg +12.5% | Goldman Sachs | $13.00 | Buy | +259.1% | Reiterated | 11.08.26on TipRanks Aug 12 10:05 | +5.2%next day −4.4% · 5 days −6.9% | ↗ |
| Whitney Ijem★★★★★★★★★★#537 · hits 48% · avg +20.2% | Canaccord Genuity | $17.00 | Buy | +369.6% | Reiterated | 11.08.26on TipRanks Aug 12 07:20 | +5.2%next day −4.4% · 5 days −6.9% | ↗ |
| Evan Seigerman★★★★★★★★★★#856 · hits 59% · avg +9.3% | BMO Capital | $14.00 | Buy | +286.7% | Reiterated | 30.06.26on TipRanks Jul 1 07:52 | +0.4%next day −2.2% · 5 days −4.5% | ↗ |
| Jack Allen★★★★★★★★★★#12322 · hits 30% · avg −16.3% | Robert W. Baird | $12.00 → $15.00+25.0% | Buy | +314.4% | Reiterated | 30.06.26on TipRanks 07:16 | +0.4%next day −2.2% · 5 days −4.5% | ↗ |
| Unknown Analyst | Jefferies | $13.00 | Buy | +259.1% | Reiterated | 23.06.26on TipRanks 09:25 | +6.5%next day +1.2% · 5 days −2.5% | ↗ |
| Silvan Tuerkcan★★★★★★★★★★#731 · hits 43% · avg +16.6% | Citizens JMP | $8.00 → $11.00+37.5% | Buy | +203.9% | Reiterated | 23.06.26on TipRanks 05:50 | +6.5%next day +1.2% · 5 days −2.5% | ↗ |
| Geulah Livshits★★★★★★★★★★#2175 · hits 35% · avg +7.2% | Chardan Capital | $12.00 | Buy | +231.5% | Reiterated | 06.05.26on TipRanks 14:50 | −0.8%next day −4.1% · 5 days −5.6% | ↗ |
| Christopher Raymond★★★★★★★★★★#4074 · hits 45% · avg +2.6% | Raymond James | $13.00 | Buy | +259.1% | Reiterated | 25.11.25on TipRanks Nov 26 07:30 | +2.9%next day +5.2% · 5 days −3.5% | ↗ |
| Joon Lee★★★★★★★★★★#73 · hits 58% · avg +36.3% | Truist Financial | — | Buy | — | Reiterated | 05.11.25on TipRanks 09:20 | −6.0%next day −1.7% · 5 days +7.3% | ↗ |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
Best analysts covering Taysha Gene Therapies
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $14.00 at a price of $4.87 (+187.5%); now: $14.00 at $3.62 (+286.7%).
PriceAverage targetTop analysts’ target
Recommendation trend
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 16 | 17 | 16 | 17 | 8 | 7 |
| Buy | 1 | 1 | 1 | 1 | 2 | 2 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 10.11.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $-0.13 (from $-0.14 to $-0.11). Last quarter: $-0.13.
Sales
Next quarter’s sales estimate — $1M (from $0M to $4M). Last quarter: $0M.
Best top-analyst consensus in the sector · Healthcare
About Taysha Gene Therapies
- CEO: Sean Nolan
- Employees: 99
- 3000 Pegasus Park Drive, Dallas, TX, 75247, US
- www.tayshagtx.com
Taysha Gene Therapies, Inc. is a biotech firm specializing in the creation and market introduction of gene therapies that utilize adeno-associated virus (AAV) vectors. Its core mission is to tackle inherited diseases affecting the central nervous system (CNS). The company's development pipeline features several key programs: TSHA-120 is aimed at giant axonal neuropathy; TSHA-102 is in development for Rett syndrome; TSHA-121 and TSHA-118 are both being advanced for CLN1 disease; TSHA-105 addresses SLC13A5 Deficiency; and TSHA-101 targets GM2 gangliosidosis. Furthermore, Taysha has forged a strategic alliance with The University of Texas Southwestern Medical Center to jointly advance and bring to market innovative gene therapy solutions. Founded in 2019, the company operates from its headquarters in Dallas, Texas.
Data from the stock’s TipRanks forecast page, read 20 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗